CD4 and pneumocystosis: In this study, we have found that, compared with the patients who continued primary or secondary prophylaxis for pneumocystosis until CD4 counts increased to ≧200 cells/μL after HAART, patients who had early discontinuation of prophylaxis were at a significantly higher risk for pneumocystosis, especially among those patients who did not adhere to HAART.